A National Study Examining the Most Effective Drainage Method After Burr Hole Evacuation of Chronic Subdural Hematoma
NCT ID: NCT06621407
Last Updated: 2025-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
354 participants
INTERVENTIONAL
2025-09-01
2027-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the current study is to test the hypothesis that 24 hours active subperiosteal drainage is non-inferior to 24 hours passive subdural drainage after single burr hole evacuation of a unilateral CSDH.
The study is a multicenter randomized non-inferiority trial encompassing all neurosurgical units in Denmark.
Adult patients with symptomatic CSDH admitted to a Danish neurosurgical unit for single burr hole evacuation will be screened for inclusion. Patients who are not able to give informed consent, and patients with recurrent CSDH, known cerebrospinal fluid abnormalities, and other known brain pathologies will be excluded. Patients with bilateral CSDH will be registered as one case and treated similarly on both sides.
Before surgical hematoma evacuation patients will be randomized to 24-hour passive subdural drainage or 24-hour active subperiosteal drainage.
The patients included and the two study statisticians will be blinded. The primary outcome is a composite outcome of 90-day mortality and symptomatic CSDH recurrence.
Secondary outcomes are 90-day simplified modified Rankin score (smRSq), and complications related to surgery or occurring during admission, including intracerebral hemorrhage due to misplaced drains, acute subdural hematoma, tension pneumocephalus, wound infection, drain seepage, subperiosteal hematoma, thromboembolic events, infections and seizures.
Sample size simulations of non-inferiority with a threshold of 7% increased relative risk show that a total of 354 participants will be required to demonstrate a relative risk reduction of recurrent CSDH and mortality of 30% for the cohort receiving active subperiosteal drainage given a stable power above 80% with an alpha of 5%. The study inclusion period is estimated to last 2 years.
Ethics approval for inclusion of competent patients has been obtained (N-20240009).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Irrigation of Chronic Subdural Hematomas - is More Better?
NCT01930617
To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation
NCT01624545
The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma
NCT02757235
Bedside Versus Operating Room Burr-Hole Drainage of Chronic Subdural Hematoma (DECIDE)
NCT03053895
Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence
NCT03831997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The subdural drain placement has, however, been much debated as drain placement through the skull burr hole in the subdural space in direct proximity to the brain may result in brain lesions, bleeding, seizures, and intracranial infections.
Therefore, burr hole craniostomy with subperiosteal drainage (also known as subgaleal drainage) has been suggested as an equally safe and effective treatment of CSDH due to less invasiveness and lower risk of drain inflicted brain parenchyma injury.
Neurosurgeons have generally been reluctant to use active (vacuum) drainage on subdural drains due to their proximity to the brain, whereas active drainage is more common active with subperiostal drainage has been more common. Although a direct comparison is lacking, it has been shown in a paper comparing three different Scandinavian centers using active subperiostal drainage, passive subdural drainage, and subdural drainage with continuously irrigation, that patients receiving passive drainage had the highest recurrence rate (20% vs. 11%) and on average a slightly higher complication rate (8.1% vs. 7.3%) and mortality rate (7.3% vs. 5.8%) compared to active subperiostal drainage which had a recurrence rate of 11.1% and a complication and mortality rate of 7.3% and 5.8%, respectively. Similarly, Post-hoc analysis of the cSDH-Drain and the TOSCAN studies have likewise revealed a higher recurrence rate (23.1% vs 14.1%) in patients receiving passive compared to active drainage.
Accordingly, as active subperiostal drainage might seem to be more safe and more efficient, the investigators find it justified to examine if 24 hours active subperiostal drainage is non-inferior to our current gold standard of 24 hours passive subdural drainage in a randomized clinical trial (the SuperDura trial).
The obtained results from the SuperDura trial will not only have major relevance for neurosurgical praxis as the investigators perform the first direct comparison between two commonly used drainage methods on a national level.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
24 hours active subperiostal drainage
24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
24 hours active subperiostal drainage
24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
24 hours passive subdural drainage
24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
24 hours passive subdural drainage
24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
24 hours active subperiostal drainage
24 hours active subperiostal drainage after single burr hole evacuation of a chronic subdural hematoma
24 hours passive subdural drainage
24 hours passive subdural drainage after single burr hole evacuation of a chronic subdural hematoma
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with symptomatic CSDH confirmed on brain CT- or magnetic resonance imaging (MRI), admitted to a Danish neurosurgical department for surgical treatment.
* Patients undergoing a single burr-hole evacuation.
* Informed written and oral consent is taken prior to surgery.
Exclusion Criteria
* Patients with known abnormalities in their cerebrospinal fluid (protein and glucose levels, cell count, and type)
* Patients with changes or abnormalities in their normal cerebrospinal fluid dynamics, e.g., obstructive hydrocephalus, normal pressure hydrocephalus, intracranial hypotension, and ventricular peritoneal shunt.
* Patients with additional/previously intracranial pathology that requires/has required neurosurgical treatment (e.g., brain tumor, vascular malformation, abscess).
* Patients with recurrent CSDH or with previous craniotomy or other transcranial surgery (for any reason)
* Patients unable to give consent prior to surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Odense University Hospital
OTHER
Rigshospitalet, Denmark
OTHER
Aarhus University Hospital
OTHER
Aalborg University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Carsten Reidies Bjarkam
Professor, Senior Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Carsten R Bjarkam, MD, PhD, DMSc
Role: STUDY_DIRECTOR
Department of Neurosurgery, Aalborg University Hospital, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Neurosurgery, Aalborg University Hospital
Aalborg, , Denmark
Department of Neurosurgery, Aarhus University Hospital
Aarhus, , Denmark
Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet
Copenhagen, , Denmark
Department of Neurosurgery, Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hjortdal Gronhoj M, Jensen TSR, Miscov R, Sindby AK, Debrabant B, Hundsholt T, Bjarkam CR, Bergholt B, Fugleholm K, Poulsen FR; DACSUHS group. Optimal drainage time after evacuation of chronic subdural haematoma (DRAIN TIME 2): a multicentre, randomised, multiarm and multistage non-inferiority trial in Denmark. Lancet Neurol. 2024 Aug;23(8):787-796. doi: 10.1016/S1474-4422(24)00175-3. Epub 2024 Jun 12.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-20240009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.